09:54 AM EST - Oncolytics Biotech Inc. : announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic non-small cell lung cancer. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.10 at $3.63.
